| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5881275 | Journal of Pain and Symptom Management | 2016 | 9 Pages |
Abstract
Chemotherapy for end-stage cancer patients is associated with higher estimated EOL care costs. Given evidence of limited benefit and potential harm of chemotherapy for end-stage cancer patients, the cost-effectiveness of such care is questioned and further study warranted.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Melissa M. PhD, Holly G. PhD, Yuhua PhD, Paul K. PhD,